Public market insider buying mushrooms at Optimi Health (OPTI)

Public market insider buying mushrooms at Optimi Health (C:OPTI)

Dane Nicholas Stevens, a Senior Officer and Director, acquired 200,000 Common Shares on an indirect ownership basis for registered holder Cathay Visions Enterprises Ltd. at a price of $0.750 on February 26th, 2021. This represents a $150,000 investment into the company's shares and an account share holdings change of 5.4%.

Three other insiders have also been buying in smaller amounts.

Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes at its wholly owned Optimi Labs Inc subsidiary (the “Research Exemption”). Optimi Labs Inc. has also applied for a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations (the “Dealer’s License”). Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production.